Publisher: Spandidos Publications
E-ISSN: 1792-1015|9|4|1413-1420
ISSN: 1792-0981
Source: Experimental and Therapeutic Medicine, Vol.9, Iss.4, 2015-01, pp. : 1413-1420
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and the third leading cause of cancerrelated mortality worldwide. Conflicting results have been reported regarding the use of serum Golgi protein 73 (GP73) as a promising serum marker for the diagnosis of HCC; therefore, the aim of the present study was to provide a systematic review of the diagnostic performance of GP73 for HCC. Following a systematic review of the relevant studies, a number of indices associated with the accuracy of the diagnostic performance of GP73, including the sensitivity and specificity, were pooled using Meta Disc 1.4 software. Data were presented as forest plots, and summary receiver operating characteristic (SROC) curve analysis was used to summarize the overall test performance. Eleven studies were included in this metaanalysis. The summary estimates for serum GP73 in diagnosing HCC were as follows: Sensitivity, 77% [95% confidence interval (CI), 7579%]; specificity, 91% (95% CI, 9092%); positive likelihood ratio, 4.34 (95% CI, 2.198.59); negative likelihood ratio, 0.30 (95% CI, 0.260.36) and diagnostic odds ratio, 15.78 (95% CI, 6.9535.83). The area under the SROC curve was 0.8638, and the Q index was 0.7944. Significant heterogeneity was found. This metaanalysis indicates a moderate diagnostic value of GP73 in HCC; however, further studies with rigorous design, large sample size and multiregional cooperation are required.
Related content
Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis
Oncology Letters, Vol. 6, Iss. 1, 2013-01 ,pp. :